| St Catherine Hospital | |
|
311 E Spruce St, Garden City, KS 67846-5614 | |
| (620) 271-3139 | |
| (620) 275-3756 |
| Full Name | St Catherine Hospital |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 311 E Spruce St, Garden City, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205549011 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| St Catherine Hospital Po Box 803929, Kansas City, MO 64180-3929 Ph: (800) 953-0104 | St Catherine Hospital 311 E Spruce St, Garden City, KS 67846-5614 Ph: (620) 271-3139 |
News Archive
Dena S. Cox, professor of marketing and faculty fellow at the Kelley School of Business Indianapolis, has received a $99,600, two-year research grant from Merck to study factors influencing young women's adoption of the human papillomavirus (HPV) vaccine.
Experts have published a list of the most urgent priorities for researching a debilitating condition that affects more than 10 million people in the UK.
One of the remaining challenges for evolutionary developmental studies of mammals, whose evolution is best known from their teeth, is how their tooth shape is altered during development.
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.
› Verified 3 days ago
Mrs. Chloe Adaire Bennett, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 311 E Spruce St, Garden City, KS 67846 Phone: 620-271-3139 | |
Miss Kim Hendricks, M.A. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 311 E Spruce St, Garden City, KS 67846 Phone: 620-275-3700 |